Logo image of EGRX

EAGLE PHARMACEUTICALS INC (EGRX) Stock Fundamental Analysis

USA - NASDAQ:EGRX - US2697961082 - Common Stock

2.14 USD
-1.42 (-39.89%)
Last: 10/2/2024, 8:06:00 PM
2.28 USD
+0.14 (+6.54%)
After Hours: 10/2/2024, 8:06:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to EGRX. EGRX was compared to 536 industry peers in the Biotechnology industry. EGRX scores excellent on profitability, but there are concerns on its financial health. EGRX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year EGRX was profitable.
EGRX had a negative operating cash flow in the past year.
Of the past 5 years EGRX 4 years were profitable.
In the past 5 years EGRX always reported a positive cash flow from operatings.
EGRX Yearly Net Income VS EBIT VS OCF VS FCFEGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M 40M 60M 80M 100M

1.2 Ratios

EGRX has a better Return On Assets (2.99%) than 94.01% of its industry peers.
Looking at the Return On Equity, with a value of 4.80%, EGRX belongs to the top of the industry, outperforming 94.54% of the companies in the same industry.
EGRX has a Return On Invested Capital of 10.53%. This is amongst the best in the industry. EGRX outperforms 95.77% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EGRX is in line with the industry average of 15.49%.
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROIC 10.53%
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
EGRX Yearly ROA, ROE, ROICEGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 10 20 30 40 50

1.3 Margins

Looking at the Profit Margin, with a value of 4.70%, EGRX belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
EGRX's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 16.47%, EGRX belongs to the best of the industry, outperforming 95.77% of the companies in the same industry.
EGRX's Operating Margin has declined in the last couple of years.
EGRX has a better Gross Margin (69.86%) than 84.33% of its industry peers.
In the last couple of years the Gross Margin of EGRX has declined.
Industry RankSector Rank
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
EGRX Yearly Profit, Operating, Gross MarginsEGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EGRX is creating some value.
EGRX has more shares outstanding than it did 1 year ago.
The debt/assets ratio for EGRX is higher compared to a year ago.
EGRX Yearly Shares OutstandingEGRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
EGRX Yearly Total Debt VS Total AssetsEGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 1.81 indicates that EGRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.81, EGRX is in the better half of the industry, outperforming 70.07% of the companies in the same industry.
EGRX has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.25, EGRX is not doing good in the industry: 68.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.81
ROIC/WACC1.32
WACC7.97%
EGRX Yearly LT Debt VS Equity VS FCFEGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

EGRX has a Current Ratio of 2.16. This indicates that EGRX is financially healthy and has no problem in meeting its short term obligations.
EGRX has a worse Current ratio (2.16) than 75.35% of its industry peers.
EGRX has a Quick Ratio of 1.67. This is a normal value and indicates that EGRX is financially healthy and should not expect problems in meeting its short term obligations.
EGRX's Quick ratio of 1.67 is on the low side compared to the rest of the industry. EGRX is outperformed by 79.58% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 1.67
EGRX Yearly Current Assets VS Current LiabilitesEGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

EGRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.52%.
The Earnings Per Share has been growing by 14.81% on average over the past years. This is quite good.
EGRX shows a decrease in Revenue. In the last year, the revenue decreased by -5.40%.
The Revenue has been growing slightly by 5.99% on average over the past years.
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%

3.2 Future

EGRX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.47% yearly.
The Revenue is expected to grow by 0.24% on average over the next years.
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EGRX Yearly Revenue VS EstimatesEGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
EGRX Yearly EPS VS EstimatesEGRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.46, the valuation of EGRX can be described as very cheap.
Based on the Price/Earnings ratio, EGRX is valued cheaper than 99.82% of the companies in the same industry.
EGRX is valuated cheaply when we compare the Price/Earnings ratio to 27.02, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 0.64, the valuation of EGRX can be described as very cheap.
EGRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. EGRX is cheaper than 99.65% of the companies in the same industry.
EGRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.57, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
EGRX Price Earnings VS Forward Price EarningsEGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

99.12% of the companies in the same industry are more expensive than EGRX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.31
EGRX Per share dataEGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The decent profitability rating of EGRX may justify a higher PE ratio.
EGRX's earnings are expected to decrease with -26.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.03
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EGRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EAGLE PHARMACEUTICALS INC

NASDAQ:EGRX (10/2/2024, 8:06:00 PM)

After market: 2.28 +0.14 (+6.54%)

2.14

-1.42 (-39.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2024-08-06/amc
Earnings (Next)11-04 2024-11-04/amc
Inst Owners66.05%
Inst Owner Change0%
Ins Owners5.97%
Ins Owner Change0%
Market Cap27.80M
Analysts85.71
Price Target17.34 (710.28%)
Short Float %0.38%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.91%
Min EPS beat(2)10.18%
Max EPS beat(2)17.65%
EPS beat(4)4
Avg EPS beat(4)19.72%
Min EPS beat(4)10.18%
Max EPS beat(4)29.93%
EPS beat(8)5
Avg EPS beat(8)-2.39%
EPS beat(12)8
Avg EPS beat(12)72.12%
EPS beat(16)11
Avg EPS beat(16)63.08%
Revenue beat(2)2
Avg Revenue beat(2)4.74%
Min Revenue beat(2)2.71%
Max Revenue beat(2)6.76%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-7.39%
Max Revenue beat(4)6.76%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)5
Avg Revenue beat(12)-7.18%
Revenue beat(16)5
Avg Revenue beat(16)-7.22%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.28
EV/EBITDA 1.31
EPS(TTM)4.66
EY217.76%
EPS(NY)3.34
Fwd EY155.86%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS19.82
BVpS19.4
TBVpS7.67
PEG (NY)N/A
PEG (5Y)0.03
Profitability
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROCE 13.33%
ROIC 10.53%
ROICexc 11.06%
ROICexgc 22.27%
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
FCFM N/A
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
ROICexc(3y)19.91%
ROICexc(5y)21.41%
ROICexgc(3y)52.27%
ROICexgc(5y)50.12%
ROCE(3y)17.2%
ROCE(5y)17.09%
ROICexcg growth 3Y46.01%
ROICexcg growth 5Y-6.15%
ROICexc growth 3Y27.58%
ROICexc growth 5Y-11.05%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
F-Score3
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 0.98
Cap/Depr 0.34%
Cap/Sales 0.03%
Interest Coverage 10.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 1.67
Altman-Z 1.81
F-Score3
WACC7.97%
ROIC/WACC1.32
Cap/Depr(3y)10.4%
Cap/Depr(5y)10.3%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
EBIT growth 1Y-45.5%
EBIT growth 3Y67.47%
EBIT growth 5Y4.32%
EBIT Next Year-37.58%
EBIT Next 3Y-26.19%
EBIT Next 5YN/A
FCF growth 1Y-121.43%
FCF growth 3Y-2.92%
FCF growth 5Y-1.22%
OCF growth 1Y-120.96%
OCF growth 3Y-3.25%
OCF growth 5Y-2.96%